Track topics on Twitter Track topics that are important to you
Harbour BioMed (HBM) completed a China Phase II trial of HBM9036 (tanfanercept), a novel TNF receptor-1 fragment indicated for moderate-to-severe Dry-Eye-Disease. In 2017, Harbour in-licensed China rights to the candidate in a two-drug deal from Korea's HanAll, which also included a treatment for pathogenic IgG-mediated autoimmune diseases. Harbour pointed out that OTC dry eye drops alleviate the symptoms of DED, but do not address the underlying inflammation. Harbour is headquartered in Boston, with operations in the Netherlands and Shanghai. More details....
Share this with colleagues:
Original Article: Harbour BioMed Completes China Phase II Trial of Dry Eye TreatmentNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...